Treating osteoporosis: antiresorptive or anabolic, and drug holidays
- Follow-up and treatment
Osteoporosis medicines cut fracture risk sharply, but each one behaves differently when it is stopped. Choosing the drug means planning its exit.
See it in 3D: Femur · L1 vertebra · L2 vertebra
What it is
Bone is constantly remodelled: osteoclasts dig, osteoblasts fill. Osteoporosis drugs either slow the diggers (antiresorptives: bisphosphonates, denosumab, raloxifene, oestrogen) or drive the fillers (anabolics: the PTH analogues teriparatide and abaloparatide, and romosozumab, an antibody to sclerostin that also slows resorption). All of them sit on a base of enough calcium and vitamin D, exercise, fall prevention and not smoking. Oral bisphosphonates are first line for most patients. Very high-risk patients (a recent fracture, several vertebral fractures, a fracture on treatment, or a very low T-score) do better starting with an anabolic, always followed by an antiresorptive to keep the gain. The drugs differ most when they are stopped: bisphosphonates stay in bone for years, so a planned «drug holiday» is possible; denosumab and the anabolics wear off within months, so another drug must follow.
What to know
- The base for everyone: enough dietary calcium and vitamin D, weight-bearing and resistance exercise, fall prevention, no smoking and little alcohol.
- Oral bisphosphonates (alendronic acid, risedronic acid, ibandronic acid) are first line; they are taken fasting with plain water, staying upright afterwards, because they are barely absorbed and irritate the oesophagus.
- Intravenous zoledronic acid suits people who cannot take or absorb tablets; the first infusion can cause a short flu-like reaction.
- Bisphosphonates are avoided when eGFR is below about 30–35 mL/min; denosumab is not cleared by the kidney but causes more hypocalcaemia in advanced CKD.
- Denosumab, an antibody to RANKL, must never simply be stopped: within months bone turnover rebounds and multiple vertebral fractures can follow, so a bisphosphonate is planned to follow it.
- Anabolics: teriparatide and abaloparatide (PTH analogues) for a limited course, romosozumab for a year (avoided after a recent heart attack or stroke); each is followed by an antiresorptive.
- Raloxifene (a SERM) protects the spine but not the hip, lowers breast cancer risk and raises venous clot risk; menopausal oestrogen also protects bone in younger women treated for symptoms.
- Rare safety facts: atypical femoral fracture (thigh or groin pain, a transverse shaft fracture) rises with years of antiresorptive use; jaw osteonecrosis is rare in osteoporosis treatment and commoner in cancer care and after dental extractions.
- Drug holiday: after about 5 years of oral or 3 years of intravenous bisphosphonate, patients whose risk has fallen may pause and be reassessed; those still at high risk continue (up to about 10 or 6 years) or switch.
Step by step
- Classify risk: high (osteoporosis or high FRAX) or very high (recent or multiple fractures, fracture on treatment, very low T-score).
- Correct vitamin D and calcium, and check creatinine and calcium, before any antiresorptive.
- Arrange dental care first if teeth need work, especially before intravenous bisphosphonate or denosumab.
- High risk: start an oral bisphosphonate; use zoledronic acid or denosumab if tablets are not possible or the kidney rules them out.
- Very high risk: start an anabolic, then switch to an antiresorptive when the course ends.
- Review adherence and side effects; repeat DXA after 1–2 years; a new fracture or a clear loss means treatment failure.
- After 3–5 years of bisphosphonate, reassess: pause if risk has fallen, continue or switch if not.
- If denosumab is stopped, start a bisphosphonate at the time the next denosumab injection would have been due.
Antiresorptive or anabolic
| Drug (class) | How it works | Main use | On stopping | Key safety points |
|---|---|---|---|---|
| Oral bisphosphonates | Bind bone mineral and switch off osteoclasts | First line in most patients | Effect lingers for years; holiday possible | Oesophagitis; avoid with low eGFR; atypical femoral fracture and jaw osteonecrosis (rare) |
| Zoledronic acid (intravenous) | Same, given by infusion | Cannot take tablets; after a hip fracture | Effect lingers for years | Acute-phase reaction; hypocalcaemia; kidney function |
| Denosumab | Antibody to RANKL; stops osteoclasts forming | Kidney disease, tablet intolerance, high risk | Rebound turnover and vertebral fractures; never stop without a follow-on drug | Hypocalcaemia, especially in CKD; jaw osteonecrosis (rare) |
| Raloxifene (SERM) | Oestrogen-like action on bone | Spine protection when breast cancer risk also matters | Effect fades | Venous thrombosis; hot flushes; no hip benefit |
| PTH analogues (teriparatide, abaloparatide) | An intermittent PTH signal builds bone | Very high risk; severe glucocorticoid osteoporosis | Gain is lost unless an antiresorptive follows | Hypercalcaemia; avoided with open growth plates, Paget disease or previous bone radiation |
| Romosozumab | Antibody to sclerostin: builds bone and slows resorption | Very high risk | Gain is lost unless an antiresorptive follows | Avoided after a recent heart attack or stroke |
In the clinic
- After a hip fracture, treatment is often forgotten: start it in hospital or at discharge; zoledronic acid after hip fracture also lowered mortality in a trial.
- Most «treatment failures» are tablets taken wrongly or not at all: ask how the patient takes them before switching.
- Fracture liaison services, in which a coordinator finds every fragility fracture, close the gap between fracture and treatment.
Next step / Initial management
- Before starting: calcium, creatinine (eGFR), 25-OH vitamin D; correct low vitamin D and calcium first.
- Follow-up: DXA after 1–2 years; bone turnover markers (CTX for antiresorptives, P1NP for anabolics) can show that the drug is working and being taken.
- Thigh or groin pain on an antiresorptive: X-ray both femurs; stop the antiresorptive if an atypical fracture is found.
- Stopping denosumab: start a bisphosphonate on schedule, without a gap.
- Refer to endocrinology very high risk needing an anabolic, a fracture on treatment, CKD stage 4–5, premenopausal women and men with unexplained osteoporosis.
Common traps
- Every osteoporosis drug can be paused after five years: only bisphosphonates, which stay in bone, allow a holiday; stopping denosumab triggers rebound vertebral fractures.
- Jaw osteonecrosis makes osteoporosis treatment too dangerous: it is rare in osteoporosis treatment, and the fractures prevented far outnumber the cases.
- An anabolic course is complete in itself: the new bone is lost within about a year unless an antiresorptive follows.
- Bisphosphonates can start while vitamin D is low: correct it first, or hypocalcaemia and a poor response follow and an osteomalacia stays untreated.
- Anabolics are a last resort after bisphosphonates fail: in very high-risk patients, starting with an anabolic prevents more fractures than starting with an antiresorptive.
Test yourself
Think of the answer, then tap the question to see it.
A 70-year-old woman stopped denosumab on her own after four years and now has three new vertebral fractures. What happened?
Rebound: as denosumab wears off, osteoclast activity overshoots and bone is lost fast, causing multiple vertebral fractures. Stopping must be covered by a bisphosphonate.
A 66-year-old woman on alendronic acid for seven years has new aching in both thighs. What must you exclude, and how?
An atypical femoral fracture: X-ray both femurs (MRI if the X-ray is normal); if found, stop the bisphosphonate and refer to orthopaedics.
Why can bisphosphonates be paused when denosumab cannot?
Bisphosphonates bind bone mineral and are released for years, so some effect remains; denosumab is an antibody cleared within months, so its effect switches off.
A 75-year-old woman with a T-score of −3.4 and two recent vertebral fractures asks which drug comes first. What is the principle?
She is at very high risk: start an anabolic (a PTH analogue or romosozumab), then follow it with an antiresorptive to keep the gain.
Elsewhere in DurgiPedia
- Osteoporosis
- Bone remodeling
- Osteoporosis after menopause
- Bone turnover markers and bone matrix proteins
- Osteonecrosis (avascular necrosis)
Connections
See it in 3D3
The structures of Durgical's 3D anatomy where it is found.
Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.
Sources: Osteoporosis in Females (StatPearls (NCBI Bookshelf), 2025); Bisphosphonate (StatPearls (NCBI Bookshelf), 2023); Denosumab (StatPearls (NCBI Bookshelf), 2024); Teriparatide (StatPearls (NCBI Bookshelf), 2024); Romosozumab (StatPearls (NCBI Bookshelf), 2024); Bisphosphonate-Related Jaw Osteonecrosis (StatPearls (NCBI Bookshelf), 2023).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
